<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02576106</url>
  </required_header>
  <id_info>
    <org_study_id>ET15-001</org_study_id>
    <nct_id>NCT02576106</nct_id>
  </id_info>
  <brief_title>Evaluation of Percutaneous Treatment by Cryoablation of Unifocal Invasive Breast Carcinoma in Menopausal Women With Indication of Lumpectomy</brief_title>
  <acronym>CRYOSE01</acronym>
  <official_title>Evaluation of Percutaneous Treatment by Cryoablation of Unifocal Invasive Breast Carcinoma in Menopausal Women With Indication of Lumpectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Leon Berard</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Leon Berard</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this monocentric and feasibility study is to review the efficacy of&#xD;
      cryotherapy in the treatment of unifocal mammary carcinomas in post-menopausal patients, with&#xD;
      lumpectomy indication.&#xD;
&#xD;
      The efficacy is defined by the rate of success of cryotherapy procedures. For each one of&#xD;
      those evaluated process, an success will be defined on the tumor sample of lumpectomy by the&#xD;
      absence of viable tumour cells.&#xD;
&#xD;
      On the basis of our expertise, it seems interesting to propose this experimental procedure to&#xD;
      patients as described above.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 2016</start_date>
  <completion_date type="Actual">January 2020</completion_date>
  <primary_completion_date type="Actual">January 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The rate of success of cryoablation procedure</measure>
    <time_frame>45 days after cryoablation</time_frame>
    <description>percentage of viable cells in the piece of lumpectomy</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Carcinoma, Ductal, Breast</condition>
  <condition>Menopausal</condition>
  <arm_group>
    <arm_group_label>Cryoablation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cryoablation of the tumor followed by a lumpectomy as practiced in standard care</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Cryoablation</intervention_name>
    <arm_group_label>Cryoablation</arm_group_label>
    <other_name>Cryotherapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Non inflammatory unilateral and unifocal breast cancer with indication of lumpectomy&#xD;
&#xD;
          -  Menopausal women with age &gt; 55 years&#xD;
&#xD;
          -  Tumor size &lt;= 15 mm by ultrasonography&#xD;
&#xD;
          -  Histological confirmation (by biopsy) of invasive ductal carcinoma with SBR&#xD;
             (Scarff-Bloom-Richardson) grade (modified by Ellis &amp; Elston) 1 or 2; hormone receptors&#xD;
             positive (Estrogen Receptor and/or Progesterone Receptor) and negative Human epidermal&#xD;
             growth factor receptor (HER2)&#xD;
&#xD;
          -  Good lesion boundary with ultrasonography and MRI&#xD;
&#xD;
          -  Minimal distance of 5 mm between the skin and the tumor&#xD;
&#xD;
          -  Performance Status 0-1&#xD;
&#xD;
          -  Ability to understand and willingness to sign a written informed consent document&#xD;
&#xD;
          -  Covered by a medical insurance&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Invasive lobular carcinoma&#xD;
&#xD;
          -  Tumor with retro-nipple location&#xD;
&#xD;
          -  Extended microcalcifications (&gt; 15 mm) with mammography&#xD;
&#xD;
          -  Xylocaine allergy&#xD;
&#xD;
          -  Patient deprived of freedom&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frank Pilleul, MD-PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Leon Berard</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre Léon Bérard</name>
      <address>
        <city>Lyon</city>
        <zip>69008</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>October 12, 2015</study_first_submitted>
  <study_first_submitted_qc>October 13, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 15, 2015</study_first_posted>
  <last_update_submitted>October 20, 2020</last_update_submitted>
  <last_update_submitted_qc>October 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Ductal</mesh_term>
    <mesh_term>Carcinoma, Ductal, Breast</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

